CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, ...

Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

Two popular medications used in the fight against obesity—semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly)—are priced too high to be considered cost-effective by currently ...

Results remained consistent across multiple sensitivity analyses and scenarios (different age populations, various assumptions), confirming the model’s reliability. Mark H. Meissner M.D., surgeon at ...